-
XW01 Subcutaneous Tissue
-
XW010 Open
-
XW0100 Brexanolone
-
XW0100 Spesolimab Monoclonal Antibody
-
XW0101 Daratumumab and Hyaluronidase-fihj
-
XW0101 Eladocagene exuparvovec
-
XW0102 Bromelain-enriched Proteolytic Enzyme
-
XW0102 Nerinitide
-
XW0103 Durvalumab Antineoplastic
-
XW0103 Maribavir Anti-infective
-
XW0104 Teclistamab Antineoplastic
-
XW0105 Mosunetuzumab Antineoplastic
-
XW0105 Narsoplimab Monoclonal Antibody
-
XW0106 Afamitresgene Autoleucel Immunotherapy
-
XW0106 Lefamulin Anti-infective
-
XW0106 Terlipressin
-
XW0107 Coagulation Factor Xa, Inactivated
-
XW0107 Tabelecleucel Immunotherapy
-
XW0107 Trilaciclib
-
XW0108 Lurbinectedin
-
XW0108 Mineral-based Topical Hemostatic Agent
-
XW0108 Treosulfan
-
XW0108 Uridine Triacetate
-
XW0109 Ceftolozane/Tazobactam Anti-infective
-
XW0109 Inebilizumab-cdon
-
XW0109 Satralizumab-mwge
-
XW010A Cefiderocol Anti-infective
-
XW010A Ciltacabtagene Autoleucel
-
XW010B Amivantamab Monoclonal Antibody
-
XW010B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW010B Omadacycline Anti-infective
-
XW010C Eculizumab
-
XW010C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW010D Atezolizumab Antineoplastic
-
XW010D Engineered Allogeneic Thymus Tissue
-
XW010E Etesevimab Monoclonal Antibody
-
XW010E Remdesivir Anti-infective
-
XW010F Bamlanivimab Monoclonal Antibody
-
XW010F Other New Technology Therapeutic Substance
-
XW010G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW010G Plazomicin Anti-infective
-
XW010G REGN-COV2 Monoclonal Antibody
-
XW010G Sarilumab
-
XW010H Axicabtagene Ciloleucel Immunotherapy
-
XW010H Other New Technology Monoclonal Antibody
-
XW010H Synthetic Human Angiotensin II
-
XW010H Tocilizumab
-
XW010J Apalutamide Antineoplastic
-
XW010J Tisagenlecleucel Immunotherapy
-
XW010K Fosfomycin Anti-infective
-
XW010K Idecabtagene Vicleucel Immunotherapy
-
XW010K Leronlimab Monoclonal Antibody
-
XW010L CD24Fc Immunomodulator
-
XW010L Erdafitinib Antineoplastic
-
XW010L Lifileucel Immunotherapy
-
XW010M Baricitinib
-
XW010M Brexucabtagene Autoleucel Immunotherapy
-
XW010M Esketamine Hydrochloride
-
XW010N Lisocabtagene Maraleucel Immunotherapy
-
XW010N Meropenem-vaborbactam Anti-infective
-
XW010P Antibiotic-eluting Bone Void Filler
-
XW010Q Tagraxofusp-erzs Antineoplastic
-
XW010R Fostamatinib
-
XW010R Venetoclax Antineoplastic
-
XW010S COVID-19 Vaccine Dose 1
-
XW010S Iobenguane I-131 Antineoplastic
-
XW010T COVID-19 Vaccine Dose 2
-
XW010T Ruxolitinib
-
XW010U COVID-19 Vaccine
-
XW010U Imipenem-cilastatin-relebactam Anti-infective
-
XW010V COVID-19 Vaccine Dose 3
-
XW010V Gilteritinib Antineoplastic
-
XW010W Caplacizumab
-
XW010W COVID-19 Vaccine Booster
-
XW010X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW010X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW010Y Other New Technology Monoclonal Antibody
-
-
XW013 Percutaneous
-
XW0130 Brexanolone
-
XW0130 Spesolimab Monoclonal Antibody
-
XW0131 Daratumumab and Hyaluronidase-fihj
-
XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
-
-
XW0131 Eladocagene exuparvovec
-
XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
-
-
XW0132 Bromelain-enriched Proteolytic Enzyme
-
XW0132 Nerinitide
-
XW0133 Durvalumab Antineoplastic
-
XW0133 Maribavir Anti-infective
-
XW0134 Teclistamab Antineoplastic
-
XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
-
-
XW0135 Mosunetuzumab Antineoplastic
-
XW0135 Narsoplimab Monoclonal Antibody
-
XW0136 Afamitresgene Autoleucel Immunotherapy
-
XW0136 Lefamulin Anti-infective
-
XW0136 Terlipressin
-
XW0137 Coagulation Factor Xa, Inactivated
-
XW0137 Tabelecleucel Immunotherapy
-
XW0137 Trilaciclib
-
XW0138 Lurbinectedin
-
XW0138 Mineral-based Topical Hemostatic Agent
-
XW0138 Treosulfan
-
XW0138 Uridine Triacetate
-
XW0139 Ceftolozane/Tazobactam Anti-infective
-
XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
-
-
XW0139 Inebilizumab-cdon
-
XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
-
-
XW0139 Satralizumab-mwge
-
XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
-
-
XW013A Cefiderocol Anti-infective
-
XW013A Ciltacabtagene Autoleucel
-
XW013B Amivantamab Monoclonal Antibody
-
XW013B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW013B Omadacycline Anti-infective
-
XW013C Eculizumab
-
XW013C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW013D Atezolizumab Antineoplastic
-
XW013D Engineered Allogeneic Thymus Tissue
-
XW013E Etesevimab Monoclonal Antibody
-
XW013E Remdesivir Anti-infective
-
XW013F Bamlanivimab Monoclonal Antibody
-
XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
-
-
XW013F Other New Technology Therapeutic Substance
-
XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
-
-
XW013G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW013G Plazomicin Anti-infective
-
XW013G REGN-COV2 Monoclonal Antibody
-
XW013G Sarilumab
-
XW013H Axicabtagene Ciloleucel Immunotherapy
-
XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013H Other New Technology Monoclonal Antibody
-
XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013H Synthetic Human Angiotensin II
-
XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013H Tocilizumab
-
XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013J Apalutamide Antineoplastic
-
XW013J Tisagenlecleucel Immunotherapy
-
XW013K Fosfomycin Anti-infective
-
XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013K Idecabtagene Vicleucel Immunotherapy
-
XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013K Leronlimab Monoclonal Antibody
-
XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013L CD24Fc Immunomodulator
-
XW013L Erdafitinib Antineoplastic
-
XW013L Lifileucel Immunotherapy
-
XW013M Baricitinib
-
XW013M Brexucabtagene Autoleucel Immunotherapy
-
XW013M Esketamine Hydrochloride
-
XW013N Lisocabtagene Maraleucel Immunotherapy
-
XW013N Meropenem-vaborbactam Anti-infective
-
XW013P Antibiotic-eluting Bone Void Filler
-
XW013Q Tagraxofusp-erzs Antineoplastic
-
XW013R Fostamatinib
-
XW013R Venetoclax Antineoplastic
-
XW013S COVID-19 Vaccine Dose 1
-
XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013S Iobenguane I-131 Antineoplastic
-
XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013T COVID-19 Vaccine Dose 2
-
XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013T Ruxolitinib
-
XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013U COVID-19 Vaccine
-
XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013U Imipenem-cilastatin-relebactam Anti-infective
-
XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
-
-
XW013V COVID-19 Vaccine Dose 3
-
XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
-
-
XW013V Gilteritinib Antineoplastic
-
XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
-
-
XW013W Caplacizumab
-
XW013W COVID-19 Vaccine Booster
-
XW013X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW013X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW013Y Other New Technology Monoclonal Antibody
-
-
XW017 Via Natural or Artificial Opening
-
XW0170 Brexanolone
-
XW0170 Spesolimab Monoclonal Antibody
-
XW0171 Daratumumab and Hyaluronidase-fihj
-
XW0171 Eladocagene exuparvovec
-
XW0172 Bromelain-enriched Proteolytic Enzyme
-
XW0172 Nerinitide
-
XW0173 Durvalumab Antineoplastic
-
XW0173 Maribavir Anti-infective
-
XW0174 Teclistamab Antineoplastic
-
XW0175 Mosunetuzumab Antineoplastic
-
XW0175 Narsoplimab Monoclonal Antibody
-
XW0176 Afamitresgene Autoleucel Immunotherapy
-
XW0176 Lefamulin Anti-infective
-
XW0176 Terlipressin
-
XW0177 Coagulation Factor Xa, Inactivated
-
XW0177 Tabelecleucel Immunotherapy
-
XW0177 Trilaciclib
-
XW0178 Lurbinectedin
-
XW0178 Mineral-based Topical Hemostatic Agent
-
XW0178 Treosulfan
-
XW0178 Uridine Triacetate
-
XW0179 Ceftolozane/Tazobactam Anti-infective
-
XW0179 Inebilizumab-cdon
-
XW0179 Satralizumab-mwge
-
XW017A Cefiderocol Anti-infective
-
XW017A Ciltacabtagene Autoleucel
-
XW017B Amivantamab Monoclonal Antibody
-
XW017B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW017B Omadacycline Anti-infective
-
XW017C Eculizumab
-
XW017C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW017D Atezolizumab Antineoplastic
-
XW017D Engineered Allogeneic Thymus Tissue
-
XW017E Etesevimab Monoclonal Antibody
-
XW017E Remdesivir Anti-infective
-
XW017F Bamlanivimab Monoclonal Antibody
-
XW017F Other New Technology Therapeutic Substance
-
XW017G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW017G Plazomicin Anti-infective
-
XW017G REGN-COV2 Monoclonal Antibody
-
XW017G Sarilumab
-
XW017H Axicabtagene Ciloleucel Immunotherapy
-
XW017H Other New Technology Monoclonal Antibody
-
XW017H Synthetic Human Angiotensin II
-
XW017H Tocilizumab
-
XW017J Apalutamide Antineoplastic
-
XW017J Tisagenlecleucel Immunotherapy
-
XW017K Fosfomycin Anti-infective
-
XW017K Idecabtagene Vicleucel Immunotherapy
-
XW017K Leronlimab Monoclonal Antibody
-
XW017L CD24Fc Immunomodulator
-
XW017L Erdafitinib Antineoplastic
-
XW017L Lifileucel Immunotherapy
-
XW017M Baricitinib
-
XW017M Brexucabtagene Autoleucel Immunotherapy
-
XW017M Esketamine Hydrochloride
-
XW017N Lisocabtagene Maraleucel Immunotherapy
-
XW017N Meropenem-vaborbactam Anti-infective
-
XW017P Antibiotic-eluting Bone Void Filler
-
XW017Q Tagraxofusp-erzs Antineoplastic
-
XW017R Fostamatinib
-
XW017R Venetoclax Antineoplastic
-
XW017S COVID-19 Vaccine Dose 1
-
XW017S Iobenguane I-131 Antineoplastic
-
XW017T COVID-19 Vaccine Dose 2
-
XW017T Ruxolitinib
-
XW017U COVID-19 Vaccine
-
XW017U Imipenem-cilastatin-relebactam Anti-infective
-
XW017V COVID-19 Vaccine Dose 3
-
XW017V Gilteritinib Antineoplastic
-
XW017W Caplacizumab
-
XW017W COVID-19 Vaccine Booster
-
XW017X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW017X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW017Y Other New Technology Monoclonal Antibody
-
-
XW018 Via Natural or Artificial Opening Endoscopic
-
XW0180 Brexanolone
-
XW0180 Spesolimab Monoclonal Antibody
-
XW0181 Daratumumab and Hyaluronidase-fihj
-
XW0181 Eladocagene exuparvovec
-
XW0182 Bromelain-enriched Proteolytic Enzyme
-
XW0182 Nerinitide
-
XW0183 Durvalumab Antineoplastic
-
XW0183 Maribavir Anti-infective
-
XW0184 Teclistamab Antineoplastic
-
XW0185 Mosunetuzumab Antineoplastic
-
XW0185 Narsoplimab Monoclonal Antibody
-
XW0186 Afamitresgene Autoleucel Immunotherapy
-
XW0186 Lefamulin Anti-infective
-
XW0186 Terlipressin
-
XW0187 Coagulation Factor Xa, Inactivated
-
XW0187 Tabelecleucel Immunotherapy
-
XW0187 Trilaciclib
-
XW0188 Lurbinectedin
-
XW0188 Mineral-based Topical Hemostatic Agent
-
XW0188 Treosulfan
-
XW0188 Uridine Triacetate
-
XW0189 Ceftolozane/Tazobactam Anti-infective
-
XW0189 Inebilizumab-cdon
-
XW0189 Satralizumab-mwge
-
XW018A Cefiderocol Anti-infective
-
XW018A Ciltacabtagene Autoleucel
-
XW018B Amivantamab Monoclonal Antibody
-
XW018B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW018B Omadacycline Anti-infective
-
XW018C Eculizumab
-
XW018C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW018D Atezolizumab Antineoplastic
-
XW018D Engineered Allogeneic Thymus Tissue
-
XW018E Etesevimab Monoclonal Antibody
-
XW018E Remdesivir Anti-infective
-
XW018F Bamlanivimab Monoclonal Antibody
-
XW018F Other New Technology Therapeutic Substance
-
XW018G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW018G Plazomicin Anti-infective
-
XW018G REGN-COV2 Monoclonal Antibody
-
XW018G Sarilumab
-
XW018H Axicabtagene Ciloleucel Immunotherapy
-
XW018H Other New Technology Monoclonal Antibody
-
XW018H Synthetic Human Angiotensin II
-
XW018H Tocilizumab
-
XW018J Apalutamide Antineoplastic
-
XW018J Tisagenlecleucel Immunotherapy
-
XW018K Fosfomycin Anti-infective
-
XW018K Idecabtagene Vicleucel Immunotherapy
-
XW018K Leronlimab Monoclonal Antibody
-
XW018L CD24Fc Immunomodulator
-
XW018L Erdafitinib Antineoplastic
-
XW018L Lifileucel Immunotherapy
-
XW018M Baricitinib
-
XW018M Brexucabtagene Autoleucel Immunotherapy
-
XW018M Esketamine Hydrochloride
-
XW018N Lisocabtagene Maraleucel Immunotherapy
-
XW018N Meropenem-vaborbactam Anti-infective
-
XW018P Antibiotic-eluting Bone Void Filler
-
XW018Q Tagraxofusp-erzs Antineoplastic
-
XW018R Fostamatinib
-
XW018R Venetoclax Antineoplastic
-
XW018S COVID-19 Vaccine Dose 1
-
XW018S Iobenguane I-131 Antineoplastic
-
XW018T COVID-19 Vaccine Dose 2
-
XW018T Ruxolitinib
-
XW018U COVID-19 Vaccine
-
XW018U Imipenem-cilastatin-relebactam Anti-infective
-
XW018V COVID-19 Vaccine Dose 3
-
XW018V Gilteritinib Antineoplastic
-
XW018W Caplacizumab
-
XW018W COVID-19 Vaccine Booster
-
XW018X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW018X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW018Y Other New Technology Monoclonal Antibody
-
-
XW01X External
-
XW01X0 Brexanolone
-
XW01X0 Spesolimab Monoclonal Antibody
-
XW01X1 Daratumumab and Hyaluronidase-fihj
-
XW01X1 Eladocagene exuparvovec
-
XW01X2 Bromelain-enriched Proteolytic Enzyme
-
XW01X27Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
-
-
XW01X2 Nerinitide
-
XW01X27Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
-
-
XW01X3 Durvalumab Antineoplastic
-
XW01X3 Maribavir Anti-infective
-
XW01X4 Teclistamab Antineoplastic
-
XW01X5 Mosunetuzumab Antineoplastic
-
XW01X5 Narsoplimab Monoclonal Antibody
-
XW01X6 Afamitresgene Autoleucel Immunotherapy
-
XW01X6 Lefamulin Anti-infective
-
XW01X6 Terlipressin
-
XW01X7 Coagulation Factor Xa, Inactivated
-
XW01X7 Tabelecleucel Immunotherapy
-
XW01X7 Trilaciclib
-
XW01X8 Lurbinectedin
-
XW01X8 Mineral-based Topical Hemostatic Agent
-
XW01X8 Treosulfan
-
XW01X8 Uridine Triacetate
-
XW01X9 Ceftolozane/Tazobactam Anti-infective
-
XW01X9 Inebilizumab-cdon
-
XW01X9 Satralizumab-mwge
-
XW01XA Cefiderocol Anti-infective
-
XW01XA Ciltacabtagene Autoleucel
-
XW01XB Amivantamab Monoclonal Antibody
-
XW01XB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW01XB Omadacycline Anti-infective
-
XW01XC Eculizumab
-
XW01XC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW01XD Atezolizumab Antineoplastic
-
XW01XD Engineered Allogeneic Thymus Tissue
-
XW01XE Etesevimab Monoclonal Antibody
-
XW01XE Remdesivir Anti-infective
-
XW01XF Bamlanivimab Monoclonal Antibody
-
XW01XF Other New Technology Therapeutic Substance
-
XW01XG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW01XG Plazomicin Anti-infective
-
XW01XG REGN-COV2 Monoclonal Antibody
-
XW01XG Sarilumab
-
XW01XH Axicabtagene Ciloleucel Immunotherapy
-
XW01XH Other New Technology Monoclonal Antibody
-
XW01XH Synthetic Human Angiotensin II
-
XW01XH Tocilizumab
-
XW01XJ Apalutamide Antineoplastic
-
XW01XJ Tisagenlecleucel Immunotherapy
-
XW01XK Fosfomycin Anti-infective
-
XW01XK Idecabtagene Vicleucel Immunotherapy
-
XW01XK Leronlimab Monoclonal Antibody
-
XW01XL CD24Fc Immunomodulator
-
XW01XL Erdafitinib Antineoplastic
-
XW01XL Lifileucel Immunotherapy
-
XW01XM Baricitinib
-
XW01XM Brexucabtagene Autoleucel Immunotherapy
-
XW01XM Esketamine Hydrochloride
-
XW01XN Lisocabtagene Maraleucel Immunotherapy
-
XW01XN Meropenem-vaborbactam Anti-infective
-
XW01XP Antibiotic-eluting Bone Void Filler
-
XW01XQ Tagraxofusp-erzs Antineoplastic
-
XW01XR Fostamatinib
-
XW01XR Venetoclax Antineoplastic
-
XW01XS COVID-19 Vaccine Dose 1
-
XW01XS Iobenguane I-131 Antineoplastic
-
XW01XT COVID-19 Vaccine Dose 2
-
XW01XT Ruxolitinib
-
XW01XU COVID-19 Vaccine
-
XW01XU Imipenem-cilastatin-relebactam Anti-infective
-
XW01XV COVID-19 Vaccine Dose 3
-
XW01XV Gilteritinib Antineoplastic
-
XW01XW Caplacizumab
-
XW01XW COVID-19 Vaccine Booster
-
XW01XX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW01XX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW01XY Other New Technology Monoclonal Antibody
-
-